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What is the best treatment 
for analgesic rebound
headaches?
■ EVIDENCE-BASED ANSWER
Abrupt discontinuation of the offending anal-
gesic(s), and treating rebound headaches with
dihydroergotamine (DHE) as needed, results in
significant improvement for most patients
(strength of recommendation [SOR]: C; based on
case series). Amitriptyline does not affect the fre-
quency or severity of rebound headaches, but it
may improve quality of life (SOR: B, low-powered
randomized controlled trial). Prednisone or 
naratriptan (Amerge) lessen acute withdrawal
symptoms from analgesics and reduce the need
for rescue medications during the first 6 days of
treatment; however, they do not affect headache
frequency or severity (SOR: B, low-quality 
randomized controlled trial). 
■ EVIDENCE SUMMARY
Analgesic rebound headaches are seen in 1% of the
population, mostly middle-aged women with under-
lying migraines.1,2 Also termed analgesic-overuse
headaches, they are defined by the International
Headache Society guidelines as headaches occur-
ring more than 15 days per month, mild to moder-
ate in intensity, developing or worsening with 
analgesic overuse, and resolving or reverting to the
prior underlying headache pattern within 2 months
of discontinuing the analgesic(s).3
A case series studied 50 patients with rebound
headaches for 5 or more days a week at baseline.4
Patients were educated regarding analgesic over-
use headaches, after which their analgesics were
abruptly discontinued, and they were followed up
to a year. Subcutaneous DHE was used as needed
for symptomatic relief of excruciating headaches.
At study completion, 78% of patients had ade-
quately stopped analgesics. The goal of greater
than 6 consecutive headache-free days was
achieved in 74% patients in an average of 84 days. 
A 9-week double-blind, placebo-controlled trial
randomized 20 nondepressed patients with anal-
gesic overuse headache to receive amitriptyline or
active placebo (trihexyphenidyl).5 Patients were
admitted to the hospital for 1 week and with-
drawn from all analgesics. The 2 groups had sim-
ilar baseline characteristics. During the hospital-
ization, the amitriptyline treatment group
received intravenous amitriptyline escalating
from 25 to 75 mg. During the following month,
oral study medications were continued, and
patients took low doses of aspirin or acetamino-
phen, as needed. There was no significant differ-
ence between the 2 groups with regard to anal-
gesic use. At completion of this low-powered
study, no difference was found between the 2
groups in headache frequency or analgesic use,
although certain components of a quality-of-life
scale were better in the amitriptyline group.
An open-label trial of patients with chronic
migraine and analgesic overuse in a headache sub-
specialty center abruptly withdrew 150 partici-
pants from analgesics and quasi-randomized them
to 3 groups: prednisone (tapering from 60 to 20 mg
over 6 days), naratriptan (Amerge) (2.5 mg twice
daily for 6 days), or no prophylactic treatment.6
Patients given the active substances were told it
would reduce withdrawal symptoms; patients
given placebo were not given this advice. All
patients received education about the pathophysi-
ology of rebound headaches, kept a headache diary,
and were phoned weekly to ensure compliance. In
addition, they all received capsules containing
gradually increasing doses of atenolol, nortripty-
line, and flunarazine (a calcium channel blocker
not FDA-approved.) Indo-methacin and chlorpro-
mazine were used as needed. Results from the first
6 days showed no difference in headaches between
the 3 groups; however, significantly more patients
used chlorpromazine in the “no pharmacologic
treatment” group 
By the end of 5 weeks, headache frequency
was significantly reduced in all groups from base-
line; however, there were no differences between
groups in headache frequency or intensity in this
C L I N I C A L  I N Q U I R I E S
278 MARCH 2005 / VOL 54, NO 3 · The Journal of Family Practice
small study. Of note, there were statistically fewer
withdrawal symptoms and less use of rescue med-
ications among patients who received the initial
prophylactic treatments. The indomethacin res-
cue use was 24%, 18%, and 14% of patients for
the no prophylactic treatment, prednisone, and
naratriptan groups respectively, while chlorpro-
mazine rescue use was 14%, 0%, and 0%, respec-
tively. The number of patients needed to treat to
prevent any withdrawal symptoms (nausea, vom-
iting, nervousness, dizziness, etc.) was 1 for every
3.5 for naratriptan, and 6.4 for prednisone. 
■ RECOMMENDATIONS FROM OTHERS
The American Council for Headache Education
recommends discontinuing all analgesics.7 It
notes some patients may need prophylactic med-
ication (although no specific agent is recommend-
ed), and hospitalization may be indicated for with-
drawal for patients who have abused narcotics.
A headache textbook recommends 1 of 2
approaches for patients undergoing outpatient
treatment: (1) gradual tapering of the offending
medication with substitution of a long-acting 
nonsteroidal anti-inflammatory drug (NSAID) and
initiation of preventive therapy, or (2) abrupt 
discontinuation of the offending medication and
initiation followed by gradual tapering of a “tran-
sitional” medication such as NSAIDs, DHE, corti-
costeroids, or triptans. The authors recommend
an intravenous DHE protocol for treatment fail-
ures and patients requiring inpatient treatment.8
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■ CLINICAL COMMENTARY
Consider anxiety, depression, substance
abuse, psychosocial stressors as triggers
Analgesic rebound headaches are clinically
challenging. Patients are reluctant to believe
that analgesic use is the cause, and good evi-
dence for pharmacologic treatment of the prob-
lem is limited. Therefore, the family physician’s
unique skills in patient-centered care are invalu-
able for helping patients comply with the only
proven remedy: long-term analgesic abstinence.
Even with intense education and support, absti-
nence rates are low and headache improvement
for abstinent patients is relatively slow and not
universal. 
In discussing options for assisting with detox-
ification, we must be honest about the limits of
our knowledge and clarify that improvement,
rather than cure, is the goal. Identification and
treatment of concurrent anxiety, depression and
substance use is important, as well as identifi-
cation of psychosocial stressors that may have
triggered increased headache frequency. As
even moderate amounts of regular analgesic use
can cause this difficult to treat syndrome, 
preventive counseling with migraine patients,
particularly those with increasing headache 
frequency, is essential.
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